drugset / Trial / NCT02415985
Pharmacokinetics and Safety of Rifabutin 150 mg Once Daily Versus Rifabutin 300 mg Thrice Weekly
Phase 2
Completed
40 enrolled
The HIV Netherlands Australia Thailand Research Collaboration
Bamrasnaradura Infectious Diseases Institute · collabChulalongkorn University · collab
RandomizedParallel-groupOpen-labelOther
Summary
To describe the pharmacokinetics of rifabutin 150 mg once daily versus rifabutin 300 mg thrice weekly in combination with LPV/r 400/100mg based HAART in HIV/TB infected patients
Timeline
- Start
- 2015-06
- Primary completion
- 2019-12
- Completion
- 2019-12
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Rifabutin | Small molecule | 150 mg | — |
| Subject | Rifabutin | Small molecule | 300 mg | — |
| Background | Lopinavir | Other / unclassified | — | — |